cb-839
Showing 1 - 8 of 8
Colorectal Cancer, Colon Cancer, Rectal Cancer Trial in Cleveland (CB-839, Capecitabine)
Active, not recruiting
- Colorectal Cancer
- +3 more
- CB-839
- Capecitabine
-
Cleveland, Ohio
- +1 more
Jan 14, 2022
Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer Trial in United States (CB-839, Talazoparib)
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial in United States (Paclitaxel, CB-839)
Completed
- Triple Negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Paclitaxel
- CB-839
-
Birmingham, Alabama
- +24 more
Sep 19, 2022
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, NSCLC (NSCLC) Trial in United States (CB-839, Nivolumab)
Completed
- Clear Cell Renal Cell Carcinoma (ccRCC)
- +2 more
- CB-839
- Nivolumab
-
Scottsdale, Arizona
- +16 more
Aug 16, 2021
Clear Cell Renal Cell Carcinoma Trial in United States (Placebo, CB-839, everolimus)
Completed
- Clear Cell Renal Cell Carcinoma
- Placebo
- +2 more
-
Tucson, Arizona
- +37 more
Aug 16, 2021
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Trial in Worldwide (CB-839, Cabozantinib, Placebo)
Completed
- Advanced Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- CB-839
- +2 more
-
Birmingham, Alabama
- +132 more
Aug 18, 2021
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM) Trial in United States (CB-839, CB-839 and
Completed
- Non-Hodgkin's Lymphoma (NHL)
- +4 more
- CB-839
- +2 more
-
Scottsdale, Arizona
- +6 more
Jul 16, 2018
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) Trial in United States (CB-839, CB-Aza)
Completed
- Acute Myeloid Leukemia (AML)
- Acute Lymphocytic Leukemia (ALL)
- CB-839
- CB-Aza
-
Denver, Colorado
- +4 more
Feb 7, 2017